Witzig TE - Search Results

1

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS. Hernandez-Ilizaliturri FJ, et al. Among authors: witzig te. Cancer. 2011 Nov 15;117(22):5058-66. doi: 10.1002/cncr.26135. Epub 2011 Apr 14. Cancer. 2011. PMID: 21495023 Free article.

2

Primary renal non-Hodgkin's lymphoma. An unusual extranodal site.

Okuno SH, Hoyer JD, Ristow K, Witzig TE. Okuno SH, et al. Among authors: witzig te. Cancer. 1995 May 1;75(9):2258-61. doi: 10.1002/1097-0142(19950501)75:9<2258::aid-cncr2820750911>3.0.co;2-s. Cancer. 1995. PMID: 7712433 Review.

3

Testicular lymphoma is associated with a high incidence of extranodal recurrence.

Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE, Egan KS, Martenson JA, Burgart LJ, Inwards DJ. Fonseca R, et al. Among authors: witzig te. Cancer. 2000 Jan 1;88(1):154-61. doi: 10.1002/(sici)1097-0142(20000101)88:1<154::aid-cncr21>3.0.co;2-t. Cancer. 2000. PMID: 10618618

4

Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. Dayharsh GA, et al. Among authors: witzig te. Gastroenterology. 2002 Jan;122(1):72-7. doi: 10.1053/gast.2002.30328. Gastroenterology. 2002. PMID: 11781282

5

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.

Gordon LI, Witzig TE, Wiseman GA, Flinn IW, Spies SS, Silverman DH, Emmanouilides C, Cripe L, Saleh M, Czuczman MS, Olejnik T, White CA, Grillo-López AJ. Gordon LI, et al. Among authors: witzig te. Semin Oncol. 2002 Feb;29(1 Suppl 2):87-92. Semin Oncol. 2002. PMID: 11842394 Review.

6

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Witzig TE, et al. J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial.

7

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Witzig TE, et al. J Clin Oncol. 2002 Aug 1;20(15):3262-9. doi: 10.1200/JCO.2002.11.017. J Clin Oncol. 2002. PMID: 12149300 Clinical Trial.

8

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C. Gordon LI, et al. Clin Lymphoma. 2004 Sep;5(2):98-101. doi: 10.3816/clm.2004.n.015. Clin Lymphoma. 2004. PMID: 15453924 Clinical Trial.

9

Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.

Ansell SM, Schilder RJ, Pieslor PC, Gordon LI, Emmanouilides C, Vo K, Czuczman MS, Witzig TE, Theuer C, Molina A. Ansell SM, et al. Among authors: witzig te. Clin Lymphoma. 2004 Dec;5(3):202-4. doi: 10.3816/clm.2004.n.028. Clin Lymphoma. 2004. PMID: 15636698 Review.

10

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.

Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR. Czuczman MS, et al. Among authors: witzig te. J Clin Oncol. 2005 Jul 1;23(19):4390-8. doi: 10.1200/JCO.2005.09.018. J Clin Oncol. 2005. PMID: 15994148 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

642 results

Search Page

Filters